Association between *Helicobacter pylori* infection and mortality risk in prostate cancer patients receiving androgen deprivation therapy: A real-world evidence study

Jui-Ming Liu¹,² | Chun-Te Wu³ | Ren-Jun Hsu⁴,⁵,⁶ | Wen-Lin Hsu⁵,⁷

¹Division of Urology, Department of Surgery, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan
²Department of Obstetrics and Gynecology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan
³Department of Urology, Chang Gung Memorial Hospital, Keelung, Taiwan
⁴Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan
⁵Cancer Center, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan
⁶School of Medicine, College of Medicine, Tzu Chi University, Hualien, Taiwan
⁷Department of Radiation Oncology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan

Correspondence
Ren-Jun Hsu and Wen-Lin Hsu, Cancer Center, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan.
Email: hsurnai@gmail.com and hwl@tzuchi.com.tw

Funding information
This study was supported by the Ministry of Science and Technology Taiwan (Grant No. MOST 104-2320-B-016-012-MY3) and grants from the Taoyuan General Hospital, Ministry of Health and Welfare (Grant Nos. PYT10801 and PTH110073).

Abstract

**Purpose:** *Helicobacter pylori* (*H. pylori*) is a major risk factor for gastric cancer and may affect androgen activity in men. The association between *H. pylori* and androgen deprivation therapy (ADT) in patients with prostate cancer (PCa) remains unclear.

**Methods:** This retrospective cohort study linked National Health Insurance (NHI) data to Taiwan Cancer Registry (TCR) and Taiwan Death Registry (TDR) between 1995 and 2016. PCa patients who received ADT were classified into *H. pylori* infection and non-*H. pylori* infection groups. The outcomes were overall mortality, prostate cancer-specific mortality, and castration-resistant prostate cancer (CRPC). Propensity score matching was adopted for the primary analysis and inverse probability of treatment weighting (IPTW) was used for the sensitivity analysis.

**Results:** Of the 62,014 selected PCa patients, 23,701 received ADT, of whom 3516 had *H. pylori* infections and 20,185 did not. After matching, there were 3022 patients in the *H. pylori* infection group and 6044 patients in the non-*H. pylori* infection group. The mean follow-up period for the matched cohort was 4.8 years. Compared to the non-*H. pylori* group, the *H. pylori* group was significantly associated with decreased risks of all-cause mortality (hazard ratio [HR] 0.90; 95% confidence interval [CI] 0.84–0.96) and prostate cancer-specific mortality (HR 0.88; 95% CI 0.81–0.95) in the matched analysis.
1 INTRODUCTION

*Helicobacter pylori* (*H. pylori*) is a gram-negative curved bacillus that colonizes the stomach and that was first described in the 1980s.\(^1\) The gastric colonization of *H. pylori* is associated with gastric cancer.\(^2\) *H. pylori* is also associated with extra-gastrointestinal diseases including cardiovascular disease, autoimmune disorders, skin disorders, and platelet disorders.\(^3,4\)

These extra-gastrointestinal phenomena of *H. pylori* may occur due to the direct effects of the bacterium, the activation of inflammatory processes resulting from cytokine release, or the mimicry between bacterial and host antigens.\(^5,6\) The prostate may also be affected by *H. pylori* as extra-gastrointestinal infection.\(^7\)

Eastern Asian populations have higher incidences of gastric cancer and lower incidences of prostate cancer (PCa) than Western countries.\(^8,9,10\) In addition, Eastern Asian populations have lower androgen-related parameters, such as testicular weight, than Caucasians. The effects of *H. pylori* may be associated with the above observations. In the elderly, *H. pylori* could modulate androgen production.\(^11\) It has further been reported that *H. pylori* is associated with lower androgen activity in men.\(^12\) Lower androgen activity may, in turn, have some beneficial effects on PCa and androgen deprivation therapy (ADT).

Prior to the present study, however, a comprehensive analysis of the relationship between *H. pylori* infection and ADT for PCa had not been undertaken. We therefore conducted the first large-scale real-world evidence study utilizing data from the National Health Insurance program of Taiwan in order to determine whether *H. pylori* is associated with the outcomes of patients receiving ADT for PCa.

1.1 PATIENTS AND METHODS

1.1.1 Data source

This retrospective cohort study linked National Health Insurance (NHI) data to Taiwan Cancer Registry (TCR) and Taiwan Death Registry (TDR) data using unique and de-identified civil identification numbers. The NHI data were taken from a national health and welfare administrative database for Taiwan’s NHI program since 1995. The NHI data were collected by the National Health Informatics Project (NHIP) and managed by the Health and Welfare Data Science Center (HWDC). We analyzed the NHI, TCR, and TDR data from 1995 to 2016. Data for gender, birth date, medications, and diagnostic codes (the International Classification of Diseases, Ninth or Tenth Revision, Clinical Modification; ICD-9-CM or ICD-10-CM) were retrieved for the analyses performed in this study.

1.2 Study population

The patients with PCas in the TCR between March 1995 and December 2016 were identified using ICD-9-CM, ICD-10-CM, or ICD-O-3 (International Classification of Diseases for Oncology, Third Edition) diagnostic codes (Table S1). The patients with PCas who received subsequent ADT therapy were then identified. The ADT categories are detailed in the Supplementary Appendix. The use of ADT therapy was detected using the Taiwan NHI reimbursement codes, which can be referred to using the anatomic therapeutic chemical (ATC) classification system\(^13\) (Table S2). The date of receiving ADT therapy for PCa was defined as the index date. Patients who were less than 40 years old; had a cancer other than PCa; or received a bilateral orchiectomy, chemotherapy, abiraterone acetate, or enzalutamide were excluded. Finally, patients who had a history of peptic ulcer disease without subsequent eradication were excluded because the status of *H. pylori* infection for these patients was unknown (Figure 1).

1.3 Definition of exposure

The exposure of interest in this study was *H. pylori* infection. The *H. pylori* infection was defined as having a diagnosis of peptic ulcer and receiving subsequent eradication therapy before the index date. In Taiwan, *H. pylori* eradication consisting of treatment with a proton pump inhibitor (PPI) or histamine receptor-2 blocker (H2 receptor blocker), clarithromycin or metronidazole, and amoxicillin or tetracycline with or without bismuth for a duration of 7–14 days is the standard treatment for *H. pylori*
Patients were divided into two groups according to the status of *H. pylori* infection. Patients with *H. pylori* infection were further divided into two subgroups according to the timing between the initial diagnosis of peptic ulcer and the eradication therapy. Patients who received *H. pylori* eradication therapy within 1 year of the diagnosis date of peptic ulcer were classified as the early eradication subgroup, while the other patients were classified as the late eradication subgroup (Figure 1).

### 1.4 Study outcomes

This study included three outcomes: all-cause mortality, PCa-specific mortality, and castration-resistant prostate cancer (CRPC). The survival status, date of death, and cause of death of patients were verified in the TDR. PCa patients diagnosed with CRPC were defined as PCa patients who received chemotherapy, abiraterone acetate, or enzalutamide. The drugs used to treat patients were also identified using the Taiwan NHI reimbursement codes (Table S3). The end dates for follow-up were extracted from the survival status in the TDR. Patients were followed until the date of death, event occurrence, or 31 December 2016, whichever came first.

### 1.5 Covariates

The covariates in this study consisted of potential confounders including age, urbanization level, monthly income, comorbidities, history of events, Charlson Comorbidity Index (CCI) score, PCa stage at diagnosis, disease extent, and medications. The demographics and socioeconomic information were included in the Registry for Beneficiaries, which is a sub-database of the NHI database. Comorbidities at the index date were identified based on having two outpatient diagnoses or a single inpatient diagnosis in the previous year. The history of a given event (e.g., cerebrovascular disease) was identified based on a single inpatient diagnosis before the index date. The ICD-9-CM and ICD-10-CM diagnostic codes for the detection of diseases are listed in Table S1. The PCa stage at diagnosis was extracted from the TCR, while medication use in the year preceding the index date was also extracted.

### 1.6 Statistical analysis

To reduce confounding due to potential selection bias, a propensity score matching (PSM) method was employed as the primary analysis in this study. The propensity score was the predicted probability of being in the *H. pylori* group given the values of covariates using logistic regression. Each patient in the *H. pylori* group was matched with two counterparts in the non-*H. pylori* group. The quality of matching was checked using the absolute value of the standardized difference (STD). As to the fatal time to event outcomes, the risks between the two groups were compared using the Cox proportional hazard model with hazard ratio (HR). The incidences of CRPC for the two groups were compared using the Fine and Gray subdistribution
hazard model\textsuperscript{15}, which considered all-cause mortality as a competing risk. PSM and the same survival analyses were also performed to compare the early eradication subgroup with the late eradication subgroup. Subgroup analysis was performed to determine whether the effects of \textit{H. pylori} infection on all-cause death and PCa-specific death were consistent among the different levels of the nine pre-specified subgroup variables listed in the Supplementary Appendix.

Sensitivity analysis was performed to assess the robustness of the primary analysis. Propensity score matching causes some amount of data loss that would reduce the statistical power. Therefore, we used inverse probability of treatment weighting (IPTW) based on the propensity scores to estimate the average treatment effect of \textit{H. pylori} infection without loss of patients in a simulated population. A two-sided \( p \) value < 0.05 was considered to be statistically significant and no adjustment of multiple testing (multiplicity) was made in this study. All statistical analyses were performed using SAS version 9.4 (SAS Institute).

2 | RESULTS

2.1 | Patient characteristics

A total of 62,014 PCa patients were selected between 1995 and 2016, of whom 44,571 received subsequent ADT. After applying the exclusion criteria, there were 23,701 remaining patients, of whom 3516 had \textit{H. pylori} infections and 20,185 did not. After matching, there were 3022 patients in the \textit{H. pylori} infection group and 6044 patients in the non-\textit{H. pylori} infection group (Figure 1). In the matched cohort, a total of 4042 patients died, including 42.5\% (1284/3022) and 45.6\% (2758/6044) of the patients in the \textit{H. pylori} infection group and the non-\textit{H. pylori} group, respectively. The mean follow-up period for the matched cohort was 4.8 years (standard deviation = 3.2 years).

The demographic characteristics of the study subjects are listed in Table 1. Before matching, the patients in the \textit{H. pylori} group had higher prevalence of hypertension, diabetes, coronary heart disease, hyperlipidemia, chronic obstructive pulmonary disease, chronic kidney disease, chronic liver disease, cerebrovascular disease, and higher CCI scores. The \textit{H. pylori} group also had more distant metastases. In addition, more patients in the \textit{H. pylori} group were prescribed non-steroidal anti-inflammatory drugs, clopidogrel, Cox-2 inhibitors, oral hypoglycemic agents, and angiotensin-converting enzyme inhibitor/angiotensin II receptor blockers. After matching, however, there were no differences between the two groups.

2.2 | All-cause mortality and prostate cancer-specific mortality

The clinical outcomes of the PCa patients who received ADT in the \textit{H. pylori} infection group and the non-\textit{H. pylori} group are shown in Table 2. Compared to the non-\textit{H. pylori} group, the \textit{H. pylori} group was significantly associated with decreased risks of all-cause mortality (HR 0.90; 95\% CI 0.84–0.96) and PCa-specific mortality (HR 0.88; 95\% CI 0.81–0.95). The decreased risks of all-cause mortality and PCa-specific mortality in the \textit{H. pylori} infection group were still observed in the sensitivity analysis by IPTW (Table S4). However, the risk of CRPC was not significantly different between the two groups (Table 2). The unadjusted cumulative event rates of all-cause mortality and PCa-specific mortality and the cumulative incidence rates of CRPC are depicted in Figure 2.

2.3 | Subgroup analysis according to \textit{H. pylori} eradication status

The pre-specified subgroup analysis results of all-cause mortality and PCa-specific mortality are shown in Figure 3. The observed decreased mortality risk from \textit{H. pylori} infection was more apparent in patients who were younger than 75 years old, without hypertension, without diabetes, and who had locoregional PCa (\( p < 0.05 \)) (Figure 3A). The observed decreased PCa-specific mortality risk was more obvious in patients who did not have diabetes and locoregional PCa (\( p < 0.05 \)) (Figure 3B).

We further compared outcomes in patients with \textit{H. pylori} infection between the early eradication and late eradication groups. The characteristics of the patients with early eradication or late eradication of \textit{H. pylori} are shown in Table S5 (PSM) and Table S6 (IPTW) in the Supplement. The results showed that there were no significant differences in all-cause mortality, PCa-specific mortality, and CRPC between the early eradication and late eradication subgroups (Table S7 and Figure S1).

3 | DISCUSSION

To the best of our knowledge, this is the first real-world evidence cohort study to investigate the association between \textit{H. pylori} infection and mortality in PCa patients receiving ADT. Using PSM analysis on 62,014 PCa patients, we demonstrated that \textit{H. pylori} infection was associated with lower risks of all-cause mortality and PCa-specific mortality in patients receiving ADT after adjustments for age, disease extent of PCa, comorbidities, and related medications. In addition, patients with early \textit{H. pylori} infection were more apparent in patients who were younger than 75 years old, without hypertension, without diabetes, and who had locoregional PCa (\( p < 0.05 \)) (Figure 3A). The observed decreased PCa-specific mortality risk was more obvious in patients who did not have diabetes and locoregional PCa (\( p < 0.05 \)) (Figure 3B).
### TABLE 1  Characteristics of the patients with and without *Helicobacter pylori* infection before and after propensity score matching

| Variables | Before matching |  |  |  | After matching |  |  |  |
|-----------|-----------------|---|---|---|-----------------|---|---|---|
|           | *H. pylori*  (n = 3516) | Non- *H. pylori*  (n = 20185) | STD |  | *H. pylori*  (n = 3022) | Non- *H. pylori*  (n = 6044) | STD |
| Age (year) | 74.4 ± 8.2 | 74.0 ± 8.4 | 0.056 |  | 74.2 ± 8.4 | 74.2 ± 8.4 | −0.003 |
| Age group |  |  |  |  |  |  |  |
| 40–49 years | 12 (0.3) | 104 (0.5) | −0.028 |  | 12 (0.4) | 19 (0.3) | 0.015 |
| 50–59 years | 165 (4.7) | 1180 (5.9) | −0.052 |  | 159 (5.3) | 315 (5.2) | 0.002 |
| 60–69 years | 799 (22.7) | 4698 (23.3) | −0.013 |  | 710 (23.5) | 1428 (23.6) | −0.003 |
| 70–79 years | 1605 (45.7) | 9295 (46.1) | −0.008 |  | 1368 (45.3) | 2720 (45.0) | 0.005 |
| ≥80 years | 935 (26.6) | 4908 (24.3) | 0.052 |  | 773 (25.6) | 1562 (25.8) | −0.006 |
| Urbanization |  |  |  |  |  |  |  |
| 1 (most urbanized) | 757 (21.5) | 4647 (23.0) | −0.036 |  | 656 (21.7) | 1270 (21.0) | 0.017 |
| 2 | 1387 (39.5) | 7717 (38.3) | 0.025 |  | 1186 (39.3) | 2378 (39.3) | −0.002 |
| 3 | 902 (25.7) | 5054 (25.0) | 0.014 |  | 782 (25.9) | 1586 (26.2) | −0.008 |
| 4 (least urbanized) | 470 (13.4) | 2767 (13.7) | −0.010 |  | 398 (13.2) | 810 (13.4) | −0.007 |
| Monthly income, NT$ |  |  |  |  |  |  |  |
| Dependent | 5 (0.1) | 22 (0.1) | 0.008 |  | 5 (0.2) | 6 (0.1) | 0.019 |
| <15,000 | 1304 (37.1) | 7737 (38.3) | −0.026 |  | 1096 (36.3) | 2184 (36.1) | 0.003 |
| 15,000–24,999 | 1350 (38.4) | 7814 (38.7) | −0.006 |  | 1176 (38.9) | 2358 (39.0) | −0.002 |
| ≥25,000 | 857 (24.4) | 4612 (22.9) | 0.036 |  | 745 (24.7) | 1496 (24.8) | −0.002 |
| Comorbidity |  |  |  |  |  |  |  |
| Hypertension | 2102 (59.8) | 8541 (42.3) | 0.355 |  | 1698 (56.2) | 3461 (57.3) | −0.022 |
| Diabetes | 813 (23.1) | 3160 (15.7) | 0.190 |  | 676 (22.4) | 1360 (22.5) | −0.003 |
| Coronary heart disease | 795 (22.6) | 2855 (14.1) | 0.220 |  | 558 (18.5) | 1122 (18.6) | −0.003 |
| Hyperlipidemia | 536 (15.2) | 1687 (8.4) | 0.214 |  | 403 (13.3) | 800 (13.2) | 0.003 |
| Atrial fibrillation | 115 (3.3) | 487 (2.4) | 0.052 |  | 97 (3.2) | 204 (3.4) | −0.010 |
| Peripheral arterial disease | 80 (2.3) | 273 (1.4) | 0.070 |  | 62 (2.1) | 117 (1.9) | 0.008 |
| COPD | 518 (14.7) | 2007 (9.9) | 0.146 |  | 398 (13.2) | 826 (13.7) | −0.015 |
| Chronic kidney disease | 477 (13.6) | 1729 (8.6) | 0.160 |  | 381 (12.6) | 769 (12.7) | −0.003 |
| Chronic liver disease | 453 (12.9) | 1146 (5.7) | 0.250 |  | 302 (10.0) | 554 (9.2) | 0.028 |
| Alcoholism | 17 (0.5) | 60 (0.3) | 0.029 |  | 15 (0.5) | 26 (0.4) | 0.010 |
| History of event |  |  |  |  |  |  |  |
| Old myocardial infarction | 101 (2.9) | 336 (1.7) | 0.081 |  | 75 (2.5) | 126 (2.1) | 0.027 |
| Heart failure | 151 (4.3) | 513 (2.5) | 0.096 |  | 112 (3.7) | 243 (4.0) | −0.016 |
| Cerebrovascular disease | 351 (10.0) | 1264 (6.3) | 0.137 |  | 269 (8.9) | 566 (9.4) | −0.016 |
| CCI score | 3.9 ± 2.5 | 2.9 ± 2.5 | 0.399 |  | 3.8 ± 2.6 | 3.7 ± 2.4 | 0.033 |
| CCI score group |  |  |  |  |  |  |  |
| 0 | 95 (2.7) | 3125 (15.5) | −0.456 |  | 95 (3.1) | 189 (3.1) | 0.001 |
| 1–2 | 955 (27.2) | 8352 (41.4) | −0.303 |  | 946 (31.3) | 1921 (31.8) | −0.010 |
| ≥3 | 2466 (70.1) | 8708 (43.1) | 0.566 |  | 1981 (65.6) | 3934 (65.1) | 0.010 |
| Prostate cancer stage at diagnosis |  |  |  |  |  |  |  |
| I | 107 (3.0) | 239 (1.2) | 0.130 |  | 71 (2.4) | 149 (2.5) | −0.008 |
| II | 801 (22.8) | 2376 (11.8) | 0.294 |  | 631 (20.9) | 1228 (20.3) | 0.014 |

(Continues)
eradication showed no statistically significant difference in mortality compared with those with late eradication. The results for 3022 *H. pylori* infection ADT patients and 6044 matched controls provide robust real-world information that should prompt physicians to be aware of the potential protective effect of *H. pylori* infection in patients treated with ADT.

There are several possible mechanisms that might explain why *H. pylori* infection reduces mortality in PCa patients receiving ADT. *H. pylori* infection may have resulted in a changed human microbiome environment. Gut microbiota may be able to regulate sex hormones. It has been reported, for example, that changing the gut microbial environment in mice changes mice testosterone levels. Hosoda et al. conducted a study to investigate the potential protective effect of *H. pylori* infection in patients treated with ADT.

---

**TABLE 1 (Continued)**

| Variables       | Before matching | After matching |
|-----------------|-----------------|---------------|
|                 | *H. pylori* (n = 3516) | Non-*H. pylori* (n = 20185) | STD | *H. pylori* (n = 3022) | Non-*H. pylori* (n = 6044) | STD |
| III             | 417 (11.9)      | 1358 (6.7)    | 0.177 | 353 (11.7)        | 702 (11.6)           | 0.002 |
| IV              | 737 (21.0)      | 2932 (14.5)   | 0.169 | 661 (21.9)        | 1346 (22.3)          | -0.010 |
| Unknown         | 1454 (41.4)     | 13280 (65.8)  | -0.505 | 1306 (43.2)       | 2619 (43.3)          | -0.002 |

Disease extent at ADT

Locoregional 2617 (74.4) 16066 (79.6) -0.123 2205 (73.0) 4402 (72.8) 0.003

Distant metastasis 899 (25.6) 4119 (20.4) 0.123 817 (27.0) 1642 (27.2) -0.003

Medication

| Variables       | Before matching | After matching |
|-----------------|-----------------|---------------|
|                 | *H. pylori* (n = 3516) | Non-*H. pylori* (n = 20185) | STD | *H. pylori* (n = 3022) | Non-*H. pylori* (n = 6044) | STD |
| NSAID           | 401 (11.4)      | 1424 (7.1)    | 0.151 | 290 (9.6)         | 592 (9.8)           | -0.006 |
| Aspirin         | 885 (25.2)      | 4735 (23.5)   | 0.040 | 787 (26.0)       | 1569 (26.0)          | 0.002 |
| Clopidogrel     | 272 (7.7)       | 351 (1.7)     | 0.285 | 89 (3.0)         | 175 (2.9)           | 0.003 |
| Cox-2 inhibitor | 219 (6.2)       | 450 (2.2)     | 0.200 | 108 (3.6)        | 213 (3.5)           | 0.003 |
| Anticoagulant agents | 70 (2.0) | 322 (1.6) | 0.029 | 60 (2.0) | 117 (1.9) | 0.004 |
| Oral hypoglycemic agents | 1058 (30.1) | 4623 (22.9) | 0.163 | 875 (29.0) | 1786 (29.6) | -0.013 |
| Insulin         | 101 (2.9)       | 402 (2.0)     | 0.057 | 84 (2.8)         | 184 (3.0)           | -0.015 |
| ACEI/ARB        | 1408 (40.1)     | 5611 (27.8)   | 0.261 | 1119 (37.0)      | 2276 (37.7)         | -0.013 |
| Follow-up years | 4.6 ± 3.1       | 5.7 ± 4.2     | -0.298 | 4.8 ± 3.2       | 4.7 ± 3.1           | 0.054 |

**TABLE 2** Follow-up outcomes of the patients with and without *Helicobacter pylori* infection

| Outcomes                        | *H. pylori* | Incidence density | Non-*H. pylori* | Incidence density | HR of *H. pylori* (95% CI) |
|---------------------------------|-------------|-------------------|-----------------|-------------------|---------------------------|
|                                | Event (%)   |                   | Event (%)       |                   |                           |
| Primary analysis: PSM           |             |                   |                 |                   |                           |
| All-cause mortality             | 1284 (42.5) | 8.81 (8.33–9.29)  | 2758 (45.6)     | 9.80 (9.43–10.16) | 0.90 (0.84–0.96)          |
| Prostate cancer-specific mortality | 906 (30.0) | 6.21 (5.81–6.62)  | 2006 (33.2)     | 7.13 (6.82–7.44)  | 0.88 (0.81–0.95)          |
| CRPC<sup>b</sup>                | 234 (7.7)   | 1.64 (1.43–1.85)  | 482 (8.0)       | 1.75 (1.59–1.90)  | 0.97 (0.83–1.13)          |
| Sensitivity analysis: IPTW<sup>a</sup> |             |                   |                 |                   |                           |
| All-cause mortality             | 50.9%       | 9.18 (9.01–9.35)  | 57.1%           | 10.27 (10.10–10.44) | 0.90 (0.81–0.99)          |
| Prostate cancer-specific mortality | 32.8%       | 5.91 (5.77–6.04)  | 40.2%           | 7.23 (7.08–7.37)  | 0.81 (0.72–0.92)          |
| CRPC<sup>b</sup>                | 8.4%        | 1.54 (1.47–1.61)  | 7.6%           | 1.39 (1.33–1.46)  | 1.13 (0.91–1.39)          |

HR, hazard ratio; CI, confidence interval; PSM, propensity score matching; IPTW, inverse probability of treatment weighting; CRPC, castration-resistant prostate cancer.

<sup>a</sup>Event values are given as %.

<sup>b</sup>Estimated using the subdistribution hazard model which considered all-cause death as a competing risk.
et al. reported that *H. pylori* absorbs and glucosylates androgens as membrane lipid components. In addition, *H. pylori* was found to be associated with lower androgen activity levels and lower levels of androstanediol glucuronide (3-alphadiol-G) (AAG), a testosterone biomarker, in older men in the NHANES III. *H. pylori* changes the

FIGURE 2  The unadjusted cumulative event rates of all-cause mortality (A), prostate cancer-specific mortality (B), and cumulative incidence function of castration-resistant prostate cancer (C) of the patients with and without *H. pylori* infection in the propensity score matched cohort.

FIGURE 3  Pre-specified subgroup analysis of all-cause mortality (A) and prostate cancer-specific mortality (B) in the propensity score matched cohort.
gut microbiome, which may lead it to metabolize sex steroid hormones and influence their activity. H. pylori also reduces androgen levels, which may have a potential benefit to ADT for PCa. Chinese populations have high incidences of gastric cancer and lower incidences of PCa than Caucasians. Meanwhile, Chinese populations also have lower androgen-related parameters, such as testicular weight, than Caucasians. The association of H. pylori with lower androgen levels may explain the above observations. Further studies are warranted, however, to achieve a better understanding of the effects of H. pylori infection.

Regimens for the eradication of H. pylori may affect androgen levels. PPIs, such as omeprazole, esomeprazole, or lansoprazole, may induce hepatic cytochrome P450 (CYP450), which increases testosterone metabolism and results, in turn, in reduced circulating testosterone levels. H2 blockers, such as cimetidine, also have effects on CYP450, including further antiandrogen effects. Metronidazole has been reported to reduce androgen and cause gynecomastia. The antiandrogen effects of these regimens may have some benefit in ADT for patients with PCa. In a recent study, PPI inhibited apoptosis and further increased survival in hormone-sensitive LNCaP cells via the ErbB2, MAPK-ERK1/2, PI3K/Akt, and GSK-3β pathways. Further studies are warranted, however, to elucidate the relationships between these regimens and ADT for PCa.

Meanwhile, H. pylori has extra-gastrointestinal phenomena, with the prostate being a possible extra-gastrointestinal colonization site. Immune responses evoked by H. pylori infection may be associated with chronic prostatitis. Proliferative inflammatory atrophy (PIA) could be induced by prostatitis, and PIA is a suspected risk factor lesion for PCa development. H. pylori may stimulate chronic systemic inflammatory responses through the production of various pro-inflammatory cytokines, such as tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ), interleukin-1β (IL-1β), interleukin-6 (IL-6), and interleukin-8 (IL-8). These pro-inflammatory cytokines may in turn be associated with aggressive PCa types. On the other hand, higher regulatory T cell (Tregs) expression levels in patients with H. pylori colonization have been reported. Tregs may down-regulate immune responses via TGF-β or IL-10 to reduce inflammatory responses. Further studies are warranted, however, to elucidate the relationships between the cytokine effects of PCa and H. pylori.

The strength of this study is a large real-world evidence study that enrolled 62,014 PCa patients with a long follow-up period. We used the PSM analysis and IPTW analysis to ensure the accuracy of the study outcomes. The study included 3022 study subjects with H. pylori infection, with the risks of all-cause mortality and PCa-specific mortality being compared among those subjects and a matched control group. Subgroup analysis with age, hypertension, diabetes, hyperlipidemia, coronary heart disease, cerebrovascular disease, chronic kidney disease, CCI score, and disease extent of PCa was also conducted to investigate the effects of H. pylori infection on the risk of PCa mortality in order to provide substantial information for physicians.

Our study has several limitations. First, the PSA levels and Gleason scores were not available in the investigated databases. It was thus difficult to further evaluate the PCa of the included subjects. In addition, several potential confounding factors, including body mass index, educational level, intestinal microbiota, and inflammation parameters were not available in the investigated databases. Second, all the diagnoses were made using the ICD-9, ICD-10, or ICD-O-3 coding systems, such that diagnostic pitfalls may have occurred. Third, the NHI database is an administrative database, such that patients’ socioeconomic status, family history, personal health behaviors, laboratory data, and image findings were not available. We did not have data to confirm the exact duration of H. pylori infection in each study subject, and the severity of H. pylori was also not available in this study. Fourth, there were no data in the investigated databases to confirm whether early or late H. pylori eradication was successful. Finally, this population-based study was a retrospective study, the association between H. pylori, intestinal microbiota, and prostate cancer may be lack of solid collateral evidence. To achieve a better understanding of the effects of H. pylori infection, further prospective studies are warranted to investigate the relationship between PCa mortality and H. pylori in patients with ADT.

4 CONCLUSIONS

This is the first real-world evidence study to demonstrate that H. pylori infection is associated with a reduced risk of mortality in PCa patients receiving ADT. This novel finding provides clinical evidence of a potential role for H. pylori infection in ADT for PCa.

AUTHORSHIP CONTRIBUTION

Liu JM and Hsu RJ thought of the concept and designed the study. Wu CT provided study materials. All authors collected and assembled data, conducted data analysis, wrote and made final approval of the manuscript.

ETHICS STATEMENT

This study was approved by the Institutional Review Board of the Tri-Service General Hospital (approval number: TSGHIRB No B-107-04). As this was a retrospective study and all data were anonymous, the Institutional
Review Board department agreed with the authors that it was waived the need for informed consent.

CONFLICT OF INTEREST
All authors declare no conflict of interest.

DATA AVAILABILITY STATEMENT
The datasets used and analyzed during the current study are not available for the restriction by the Institutional Review Board of the Tri-Service General Hospital.

ORCID
Ren-Jun Hsu https://orcid.org/0000-0003-2877-9215

REFERENCES
1. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984;1:1311–1315.
2. Nomura A, Stemmermann GN, Chyou PH, Kato I, Perez-Perez GI, Blaser MJ. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med. 1991;325:1132–1136.
3. Kowalski M. Helicobacter pylori (H. pylori) infection in coronary artery disease: influence of H. pylori eradication on coronary artery lumen after percutaneous transluminal coronary angioplasty. The detection of H. pylori specific DNA in human coronary atherosclerotic plaque. J Physiol Pharmacol. 2001;52:3–31.
4. Zhou D, Zhang Y, Gong W, et al. Are Helicobacter pylori and other Helicobacter species infection associated with human bilateral litihsis? A meta-analysis. Plos One. 2001;6:e27390.
5. Appelmelk BJ, Simoons Smit I, Negrini R, et al. Potential role of molecular mimicry between Helicobacter pylori lipopolysaccharide and host Lewis blood group antigens in autoimmunity. Infect Immun. 1996;64:2031–2040.
6. Ko GH, Park HB, Shin MK, et al. Monoclonal antibodies against Helicobacter pylori cross-react with human tissue. Helicobacter. 1997;2:210–215.
7. Abdollahi A, Etemadian M, Shoar S, Nozarian Z. Is Helicobacter pylori infection a risk factor for Prostatitis? A case-control study in a Referring Tertiary Care Center. Iran J Pathol. 2016;11:323–327.
8. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin. 1972;22:232–240.
9. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E386.
10. Center MM, Jemal A, Lorret-Tieulent J, Ward E, Ferlay J, Brawley O. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012;61:1079–1092.
11. Markle JG, Frank DN, Mortin-Toth S, et al. Sex differences in the gut microbiome drive hormone dependent regulation of autoimmunity. Science. 2013;339:1084–1088.
12. Schooling CM, Dowd JB, Jones HE. Helicobacter pylori is associated with lower androgen activity among men in NHANES III. Gut. 2013;62:1384–1385.
13. Liu JM, Yu CP, Chuang HC, Wu CT, Hsu RJ. Androgen deprivation therapy for prostate cancer and the risk of autoimmune diseases. Prostate Cancer Prostatic Dis. 2019;22:475–482.
14. Wu CY, Kuo KN, Wu MS, Chen YJ, Wang CB, Lin JT. Early Helicobacter pylori eradication decreases risk of gastric cancer in patients with peptic ulcer disease. Gastroenterology. 2009;137:1641–1648.
15. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496–509.
16. Hosoda K, Shimomura H, Hayashi S, Yokota K, Oguma K, Hirai Y. Anabolic utilization of steroid hormones in Helicobacter pylori. FEMS Microbiol Lett. 2009;297:173–179.
17. Lombardi P, Goldin B, Boutin E, Gorbach SL. Metabolism of androgens and estrogens by human fecal microorganisms. J Steroid Biochem. 1978;9:795–801.
18. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010;19:1893–1907.
19. Johnson L, Barnard JJ, Rodriguez L, et al. Ethnic differences in testicular structure and spermatogenetic potential may predispose testes of Asian men to a heightened sensitivity to steroidoidal contraceptives. J Androl. 1998;19:348–357.
20. Rosenshein B, Flockhart DA, Ho H. Induction of testosterone metabolism by esomeprazole in a CYP2C19*2 heterozygote. Am J Med Sci. 2004;327:289–293.
21. Santucci L, Farroni F, Fiorucci S, Morelli A. Gynecomastia during omeprazole therapy. N Engl J Med. 1991;324:635.
22. García Rodríguez LA, Jick H. Risk of gynaecomastia associated with cimetidine, omeprazole, and other antiulcer drugs. BMJ. 1994;308:503–506.
23. Fagan TC, Johnson DG, Grosso DS. Metronidazole-induced gynaecomastia. JAMA. 1985;254:3217.
24. Gesmundi I, Di Blasio L, Banfi D, et al. Proton pump inhibitors promote the growth of androgen-sensitive prostate cancer cells through ErbB2, ERK1/2, PI3K/Akt, GSK-3β signaling and inhibition of cellular prostatic acid phosphatase. Cancer Lett. 2019;449:252–262.
25. Karatas OF, Turkyay C, Bayrak O, Cimentepe E, Unal D. Helicobacter pylori seroprevalence in patients with chronic prostatitis: a pilot study, Scand J Urol Nephrol. 2010;44:91–94.
26. Dennis LK, Lynch CF, Torner JC. Epidemiologic association between prostate and prostate cancer. Urology. 2002;60:78–83.
27. De Marzo AM, Marchi VL, Epstein JI, Nelson WG. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol. 1999;155:1985–1992.
28. El-Omar EM. The importance of interleukin 1beta in Helicobacter pylori associated disease. Gut. 2001;48:743–747.
29. Crabtree JE. Role of cytokines in pathogenesis of Helicobacter pylori-induced mucosal damage. Dig Dis Sci. 1998;43:46S–55S.
30. Nguyen DP, Li J, Tewari AK. Inflammation and prostate cancer: the role of interleukin 6 (IL-6). BIU Int. 2014;113:986–992.
31. Mahon KL, Lin H-M, Castillo L, et al. Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer. Br J Cancer. 2015;112:1340–1348.
32. Wise GJ, Marella VK, Talluri G, Shirazian D. Cytokine variations in patients with hormone treated prostate cancer. J Urol. 2000;164:722–725.
33. Robinson K, Kenebeck R, Pidgeon EL, et al. Helicobacter pylori-induced peptic ulcer disease is associated with inadequate regulatory T cell responses. Gut. 2008;57:1375–1385.
34. Arnold IC, Dehzad N, Reuter S, et al. Helicobacter pylori infection prevents allergic asthma in mouse models through the induction of regulatory T cells. J Clin Invest. 2011;121:3088–3093.
35. Oertli M, Sundquist M, Hitzler I, et al. DC-derived IL-18 drives Treg differentiation, murine Helicobacter pylori-specific immune tolerance, and asthma protection. *J Clin Invest.* 2012;122:1082–1096.

**SUPPORTING INFORMATION**
Additional Supporting Information may be found in the online version of the article at the publisher’s website.

**How to cite this article:** Liu J-M, Wu C-T, Hsu R-J, Hsu W-L. Association between Helicobacter pylori infection and mortality risk in prostate cancer patients receiving androgen deprivation therapy: A real-world evidence study. *Cancer Med.* 2021;10:8162–8171. doi:[10.1002/cam4.4318](https://doi.org/10.1002/cam4.4318)